Progress in PBC: Seladelpar in Trial as Second-Line Therapy
Gastroenterology Learning Network
00:00
Investigating the Efficacy of Seladelpar for PBC Treatment
This chapter explores the effectiveness of seladelpar, a selective PPAR delta agonist, as a potential treatment for primary biliary cholangitis (PBC). It discusses the results of a study that found significant improvement in liver tests, serum biochemistry, and symptom relief after three months of treatment with seladelpar.
Transcript
Play full episode
